Despite advances in cancer biology and therapeutics, drug resistance remains problematic.
Resistance is often multifactorial, heterogeneous, and prone to undersampling …

Decades of research into the molecular mechanisms of cancer and the development of
novel therapeutics have yielded a number of remarkable successes. However, our ability to …

Cancer drug resistance continues to be a major impediment in medical oncology. Clinically,
resistance can arise prior to or as a result of cancer therapy. In this review, we discuss …

The introduction of targeted therapy promised personalized and efficacious cancer
treatments. However, although some targeted therapies have undoubtedly improved …

Despite continuous deployment of new treatment strategies and agents over many decades,
most disseminated cancers remain fatal. Cancer cells, through their access to the vast …

Driver mutations promote initiation and progression of cancer. Pharmacological treatment
can inhibit the action of the mutant protein; however, drug resistance almost invariably …

Despite high initial efficacy, targeted therapies eventually fail in advanced cancers, as
tumors develop resistance and relapse. In contrast to the substantial body of research on the …

Most experimental cancer drugs ultimately fail during the course of clinical development,
contributing to the high cost of the few that are granted regulatory approval. Moreover …

All successful cancer therapies are limited by the development of drug resistance. The
increase in the understanding of the molecular and biochemical bases of drug efficacy has …

Identification of the genomic drivers of cancer has led to the clinical development of targeted
therapies that strike at the heart of many malignancies. Nonetheless, many cancers outsmart …